A carregar...
Interleukin 6 is increased in preclinical HNSCC models of acquired cetuximab resistance, but is not required for maintenance of resistance
The epidermal growth factor receptor inhibitor cetuximab is the only oncogene-targeted agent that has been FDA approved for the treatment of head and neck squamous cell carcinoma (HNSCC). Currently, there are no biomarkers used in the clinic to predict which HNSCC tumors will respond to cetuximab, a...
Na minha lista:
| Publicado no: | PLoS One |
|---|---|
| Main Authors: | , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Public Library of Science
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6948745/ https://ncbi.nlm.nih.gov/pubmed/31914141 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0227261 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|